-
2024-511346-39-00
3
2025-03-28
Immune-mediated necrotizing myopathy
-
2024-513018-36-00
5
2025-03-06
Lung Diseases, Interstitial
-
2024-512484-31-00
4
2025-02-28
FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach
-
2024-516869-36-00
1
2025-02-17
Relapsed or refractory B-cell malignancies: chronic lymphocytic leukem
-
2024-513317-12-00
5
2025-02-05
Pancreatic cancer
-
2024-513077-48-00
5
2024-12-19
O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2023-509482-20-00
4
2024-12-03
Solid Tumors
-
2024-514135-17-00
5
2024-11-28
Immunoglobulin A Nephropathy
-
2024-512423-36-00
5
2024-11-20
Undifferentiated pleomorphic sarcoma
-
2023-506757-38-00
1
2024-11-14
Advanced/metastatic solid tumors that are MTAP deficient.
-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
-
2023-508805-26-00
1
2024-10-23
patients with active brain metastases, where the primary tumour has co
-
2023-504231-41-01
10
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-504445-31-00
4
2024-09-19
Carcinoma, Head and Neck
-
2023-506227-29-00
3
2024-08-30
locally advanced or metastatic solid tumors
-
2024-512839-70-00
1
2024-08-27
Advanced and/or Metastatic Solid Tumors
-
2023-509566-38-00
9
2024-08-05
gastroesophageal junction adenocarcinoma
-
2023-503699-25-00
5
2024-07-15
Progressive Pulmonary Fibrosis
-
2023-508441-41-00
6
2024-07-08
Bacteriemia producida por P. aeruginosa.
-
2022-502359-75-00
5
2024-07-03
Dravet syndrome
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2023-504245-32-00
4
2024-06-06
Eosinophilic granulomatosis with polyangiitis (EGPA)
-
2023-503221-19-00
4
2024-04-18
Advanced Non-Small Cell Lung Cancer